Cepheid (company) (English Wikipedia)

See Harold Marsh, Jr., R. Roy Finkle, Larry W. Sonsini, and Ann Yvonne Walker, Marsh's California Corporation Law, 4th ed., vol. 1 (New York: Aspen Publishers, 2004), 5–15 — 5–16.

cbc.ca

Mahdavi, Darius (September 19, 2023). "'Pure price-gouging': Advocates celebrate price drop of critical TB test but say Big Pharma needs to do more". CBC.

cdc.gov

wwwn.cdc.gov

"Test Complexities". wwwn.cdc.gov. Retrieved April 17, 2017.

cepheid.com

ir.cepheid.com

"FAQs - Cepheid". Archived from the original on May 29, 2014. Retrieved May 29, 2014.

doctorswithoutborders.org

(19 September 2023). MSF: TB test price reduction by Cepheid and Danaher is a step in the right direction, Doctors Without Borders

doi.org

Gotham, Dzintars; McKenna, Lindsay; Deborggraeve, Stijn; Madoori, Suraj; Branigan, David (August 31, 2021). "Public investments in the development of GeneXpert molecular diagnostic technology". PLOS ONE. 16 (8): e0256883. Bibcode:2021PLoSO..1656883G. doi:10.1371/journal.pone.0256883. PMC 8407584. PMID 34464413.

eastbaytimes.com

"Sunnyvale company wins FDA approval for first rapid coronavirus test with 45-minute detection time". EastBayTimes.com. March 21, 2020. Archived from the original on March 22, 2020.

fiercebiotech.com

Hale, Chris (February 28, 2020). "Sherlock Bio, Cepheid pair up to develop CRISPR diagnostics for coronavirus and more". Fierce Biotech. Archived from the original on March 6, 2020.

financialcontent.com

markets.financialcontent.com

"2006 Industrial Design Excellence Awards". Markets.financialcontent.com. July 5, 2006. Archived from the original on March 9, 2014. Retrieved March 9, 2014.

gatesfoundation.org

(6 August 2012). Public-Private Partnership Announces Immediate 40 Percent Cost Reduction for Rapid TB Test, Gates Foundation, Retrieved 15 September 2023

goodgoodgood.co

Baker, Kamrin (September 12, 2023). "John Green & Grassroots Activists Pressure Danaher To Drop Price of Tuberculosis Test". Good Good Good.

harvard.edu

ui.adsabs.harvard.edu

Gotham, Dzintars; McKenna, Lindsay; Deborggraeve, Stijn; Madoori, Suraj; Branigan, David (August 31, 2021). "Public investments in the development of GeneXpert molecular diagnostic technology". PLOS ONE. 16 (8): e0256883. Bibcode:2021PLoSO..1656883G. doi:10.1371/journal.pone.0256883. PMC 8407584. PMID 34464413.

healthpolicy-watch.org

Fletcher, Elaine; Vijay, Svĕt (March 23, 2020). "New COVID-19 Rapid Diagnostic Approved On 'GeneXpert' TB Platform; Could Pave Way For More Testing In Low- & Middle-Income Countries". HealthPolicy-Watch.org. Archived from the original on April 4, 2020.
Ren, Grace (March 24, 2020). "Médecins Sans Frontières Announces Campaign For $5 COVID-19 Test On 'GeneXpert' TB Platform". Health Policy Watch.

highbeam.com

"Contract Award: Cepheid Wins Federal Contract for "MRSA Reagent". April 16, 2012. Archived from the original on June 11, 2014. Retrieved March 9, 2014.

ieee.org

spectrum.ieee.org

Perry, Tekla (April 7, 2020). "A Rapid Test for Covid-19 Arrives Via a 20-year-old Technology Already in Many Hospitals". IEEE Spectrum: Technology, Engineering, and Science News. IEEE.

marketwatch.com

"CPHD Key Statistics – Cepheid Financial Ratios". MarketWatch. Archived from the original on August 3, 2016.
"CPHD Stock Quote – Cepheid Stock Price Today (CPHD:NASDAQ) – MarketWatch". MarketWatch. August 16, 2016. Archived from the original on August 17, 2016.

meddeviceonline.com

Enriquez, Jof. "Danaher Buys Molecular Diagnostics Firm Cepheid For 4 Billion". www.meddeviceonline.com.

mercurynews.com

"Sunnyvale company wins FDA approval for first rapid coronavirus test with 45-minute detection time". The Mercury News. Reuters. March 21, 2020.

msf.org

"No profiteering on COVID-19 drugs and vaccines, says MSF". Médecins Sans Frontières (MSF) International.

msfaccess.org

"Time for $5: GeneXpert diagnostic tests". Médecins Sans Frontières Access Campaign. Technical Brief. July 13, 2023.

msn.com

Brits, Elsabé (March 7, 2020). "Covid-19: How South Africa will test for the virus". www.msn.com. Archived from the original on April 12, 2020. Retrieved May 1, 2020.

nih.gov

ncbi.nlm.nih.gov

Gotham, Dzintars; McKenna, Lindsay; Deborggraeve, Stijn; Madoori, Suraj; Branigan, David (August 31, 2021). "Public investments in the development of GeneXpert molecular diagnostic technology". PLOS ONE. 16 (8): e0256883. Bibcode:2021PLoSO..1656883G. doi:10.1371/journal.pone.0256883. PMC 8407584. PMID 34464413.

pubmed.ncbi.nlm.nih.gov

Gotham, Dzintars; McKenna, Lindsay; Deborggraeve, Stijn; Madoori, Suraj; Branigan, David (August 31, 2021). "Public investments in the development of GeneXpert molecular diagnostic technology". PLOS ONE. 16 (8): e0256883. Bibcode:2021PLoSO..1656883G. doi:10.1371/journal.pone.0256883. PMC 8407584. PMID 34464413.

reuters.com

"Cepheid (CPHD.O) Company Profile". Reuters. Archived from the original on March 4, 2016. Retrieved March 22, 2020.
Singh, Kanishka (March 22, 2020). "U.S. FDA approves first rapid coronavirus test with 45 minutes detection time". Reuters. Retrieved March 22, 2020.
(8 August 2012). Cepheid inks deals to sell TB test in developing nations, Reuters
Reuters Editorial. "Company Search Results". Reuters. Archived from the original on November 8, 2016. Retrieved April 17, 2017. {{cite web}}: |author= has generic name (help)
Grover, Natalie (September 6, 2016). "Danaher to buy Cepheid in $4 billion deal to expand in diagnostics". Reuters.

sfgate.com

Emert, Carol (21 October 2001). Detecting disease / Cepheid's stock price rises as Sunnyvale firm's device to ID anthrax gains attention, San Francisco Chronicle
"Biotech firms turn to antiterrorism efforts / Cepheid makes anthrax detectors". SFGate. Retrieved April 17, 2017.
"Biotech firms turn to antiterrorism efforts / Cepheid makes anthrax detectors". SFGate. Retrieved March 22, 2020.

shareholder.com

files.shareholder.com

"Archived copy" (PDF). Archived from the original (PDF) on May 31, 2014. Retrieved May 30, 2014.{{cite web}}: CS1 maint: archived copy as title (link)

statnews.com

Lawrence, Lizzy; Silverman, Ed (September 14, 2023). "Novelist John Green launches attack on Cepheid over the price of its TB test". Stat. Retrieved September 14, 2023.

tbonline.info

"OPEN LETTER: Time to Lower the Price of Xpert Cartridges to US$ 5" (PDF). TBOnline. October 21, 2019. Retrieved May 2, 2020.

thefreelibrary.com

"Cepheid Xpert GBS(TM) Test Categorized as 'Moderate Complexity'". www.thefreelibrary.com. Archived from the original on January 9, 2017. Retrieved April 17, 2017.

thejakartapost.com

"Indonesian government could use TB test kits for COVID-19, doctor says". The Jakarta Post.

theunion.org

"World TB Day statement on CEPHEID rapid testing for COVID-19". The Union. March 24, 2020.

treatmentactiongroup.org

"Treatment Action Group Statement on the High Price of Cepheid's Xpert Test for COVID-19". Treatment Action Group.

web.archive.org

"CPHD Key Statistics – Cepheid Financial Ratios". MarketWatch. Archived from the original on August 3, 2016.
"Cepheid (CPHD.O) Company Profile". Reuters. Archived from the original on March 4, 2016. Retrieved March 22, 2020.
Brits, Elsabé (March 7, 2020). "Covid-19: How South Africa will test for the virus". www.msn.com. Archived from the original on April 12, 2020. Retrieved May 1, 2020.
"Cepheid's Xpert GBS(TM) Test Receives 510(k) Clearance From FDA". Archived from the original on May 31, 2014. Retrieved May 30, 2014.
"Cepheid Xpert GBS(TM) Test Categorized as 'Moderate Complexity'". www.thefreelibrary.com. Archived from the original on January 9, 2017. Retrieved April 17, 2017.
"Contract Award: Cepheid Wins Federal Contract for "MRSA Reagent". April 16, 2012. Archived from the original on June 11, 2014. Retrieved March 9, 2014.
"Archived copy" (PDF). Archived from the original (PDF) on May 31, 2014. Retrieved May 30, 2014.{{cite web}}: CS1 maint: archived copy as title (link)
Fletcher, Elaine; Vijay, Svĕt (March 23, 2020). "New COVID-19 Rapid Diagnostic Approved On 'GeneXpert' TB Platform; Could Pave Way For More Testing In Low- & Middle-Income Countries". HealthPolicy-Watch.org. Archived from the original on April 4, 2020.
Hale, Chris (February 28, 2020). "Sherlock Bio, Cepheid pair up to develop CRISPR diagnostics for coronavirus and more". Fierce Biotech. Archived from the original on March 6, 2020.
"FAQs - Cepheid". Archived from the original on May 29, 2014. Retrieved May 29, 2014.
Reuters Editorial. "Company Search Results". Reuters. Archived from the original on November 8, 2016. Retrieved April 17, 2017. {{cite web}}: |author= has generic name (help)
"CPHD Stock Quote – Cepheid Stock Price Today (CPHD:NASDAQ) – MarketWatch". MarketWatch. August 16, 2016. Archived from the original on August 17, 2016.

wsj.com

Hufford, Austen (September 6, 2016). "Danaher to Buy Diagnostics Company Cepheid for $4 Billion". Wall Street Journal.

youtube.com

Green, John (September 12, 2023). "Barely Contained Rage: An Open Letter to Danaher and Cepheid" (video). youtube.com. Vlogbrothers.